SCHEMBL4466423

SCHEMBL4466423

Fc1[c]c2ccccc2[nH]1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
HSD17B10 Q99714 2/20 0.35
GPR3 P46089 1/20 0.35
KDM4E B2RXH2 2/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
PSMB8 P28062 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
AHR P35869 1/20 0.30
LMNA P02545 1/20 0.30
GLA P06280 1/20 0.30
GAA P10253 1/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11785225 0.75 ALDH1A1 (0.38) ALDH1A1HSD17B10GPR3KDM4EGRIN2D
SCHEMBL8588800 0.71 ALDH1A1 (0.40) ALDH1A1HSD17B10GPR3KDM4EGRIN2D
SCHEMBL1388471 0.71 ALDH1A1 (0.35) ALDH1A1HSD17B10GPR3KDM4EGRIN2D
SCHEMBL29547 0.71 AHR (0.37) ALDH1A1HSD17B10GPR3KDM4EGRIN2D
SCHEMBL2230518 0.71 ALDH1A1 (0.35) ALDH1A1HSD17B10GPR3KDM4EGRIN2D
SCHEMBL9797375 0.71 NPSR1 (0.37) ALDH1A1HSD17B10GPR3KDM4EGRIN2D
SCHEMBL28824470 0.70 AHR (0.35) ALDH1A1HSD17B10GPR3KDM4EGRIN2D
SCHEMBL1972818 0.68 NPC1 (0.41) ALDH1A1HSD17B10GPR3KDM4EGRIN2D
SCHEMBL67229 0.68 KIF11 (0.36) ALDH1A1HSD17B10GPR3KDM4EGRIN2D
SCHEMBL10813818 0.68 ALDH1A1 (0.32) ALDH1A1HSD17B10GPR3KDM4EGRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4870087-A Indole containing, 2-thienyl-1,2,3,6-tetrahydropyridyls and their pharmaceutical use MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1989-09-26 US claimed
US-4617309-A Sulfur-containing indole derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1986-10-14 US claimed
CN-101563320-B [2- (6-fluoro-1H-indol-3-ylsulfanyl) benzyl ] methylamine for the treatment of affective disorders LUNDBECK & CO AS H 2012-05-30 CN disclosed
CN-101563320-A [ 2- (6-fluoro-1H-indol-3-ylsulfanyl) benzyl ] methylamine for the treatment of affective disorders LUNDBECK & CO AS H (DK) 2009-10-21 CN disclosed
US-7521454-B2 Adenine derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-04-21 US disclosed
EP-1386923-B1 NOVEL ADENINE DERIVATIVES DAINIPPON SUMITOMO PHARMA CO (JP) 2008-08-13 EP disclosed
US-20070037832-A1 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-02-15 US disclosed
US-7157465-B2 Adenine derivatives DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) 2007-01-02 US disclosed
CN-1250548-C Novel adenine derivatives SUMITOMO PHARMA (JP) 2006-04-12 CN disclosed
CN-1512992-A Novel adenine derivatives ס����ҩ��ʽ���� 2004-07-14 CN disclosed
US-20040132748-A1 Novel adenne derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-08 US disclosed
EP-1386923-A1 NOVEL ADENINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-02-04 EP disclosed
US-4870087-A Indole containing, 2-thienyl-1,2,3,6-tetrahydropyridyls and their pharmaceutical use MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1989-09-26 US disclosed
EP-0121716-B1 INDOLE DERIVATIVES MERCK PATENT GmbH (DE) 1987-12-09 EP disclosed
US-4617309-A Sulfur-containing indole derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1986-10-14 US disclosed
EP-0105397-B1 SULPHURIC INDOLE DERIVATIVES MERCK PATENT GmbH (DE) 1986-07-16 EP disclosed
EP-0121716-A1 Indole derivatives MERCK PATENT GmbH (DE) 1984-10-17 EP disclosed
EP-0114603-A1 Indole derivatives MERCK PATENT GmbH (DE) 1984-08-01 EP disclosed
EP-0105397-A1 Sulphuric indole derivatives MERCK PATENT GmbH (DE) 1984-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132748-A1 Novel adenne derivatives IRF3, IFNAR1, STING1 ALDH1A1 1181/4885HSD17B10 2026/4885GPR3 497/4885
US-20070037832-A1 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis IRF3, IFNAR1, IFNG ALDH1A1 2467/4885HSD17B10 1456/4885GPR3 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.